Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering...

Descripción completa

Detalles Bibliográficos
Autores principales: Abate-Daga, Daniel, Rosenberg, Steven A, Morgan, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108460/
https://www.ncbi.nlm.nih.gov/pubmed/25083334
http://dx.doi.org/10.4161/onci.29194
_version_ 1782327761904336896
author Abate-Daga, Daniel
Rosenberg, Steven A
Morgan, Richard A
author_facet Abate-Daga, Daniel
Rosenberg, Steven A
Morgan, Richard A
author_sort Abate-Daga, Daniel
collection PubMed
description Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent on-target/off-tumor toxicities.
format Online
Article
Text
id pubmed-4108460
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41084602014-07-31 Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies Abate-Daga, Daniel Rosenberg, Steven A Morgan, Richard A Oncoimmunology Author's View Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent on-target/off-tumor toxicities. Landes Bioscience 2014-06-18 /pmc/articles/PMC4108460/ /pubmed/25083334 http://dx.doi.org/10.4161/onci.29194 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Abate-Daga, Daniel
Rosenberg, Steven A
Morgan, Richard A
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title_full Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title_fullStr Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title_full_unstemmed Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title_short Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
title_sort pancreatic cancer: hurdles in the engineering of car-based immunotherapies
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108460/
https://www.ncbi.nlm.nih.gov/pubmed/25083334
http://dx.doi.org/10.4161/onci.29194
work_keys_str_mv AT abatedagadaniel pancreaticcancerhurdlesintheengineeringofcarbasedimmunotherapies
AT rosenbergstevena pancreaticcancerhurdlesintheengineeringofcarbasedimmunotherapies
AT morganricharda pancreaticcancerhurdlesintheengineeringofcarbasedimmunotherapies

Ejemplares similares